Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Merck is planning to look at the combination of Lenvima and Keytruda in previously-untreated patients, while Roche recently picked up an FDA breakthrough designation for its PD-L1 inhibitor ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Keytruda sales beat the Zacks Consensus Estimate of $7.38 billion and our estimate of $7.31 billion. Alliance revenues from Lynparza and Lenvima also boosted oncology sales in the quarter.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...